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Abstract
Background: The growth of tumor cells is accompanied by mutations in nuclear and mitochondrial genomes
creating marked genetic heterogeneity. Tumors also contain non-tumor cells of various origins. An observed somatic
mitochondrial mutation would have occurred in a founding cell and spread through cell division. Micro-anatomical
dissection of a tumor coupled with assays for mitochondrial point mutations permits new insights into this growth
process. More generally, the ability to detect and trace, at a histological level, somatic mitochondrial mutations in human
tissues and tumors, makes these mutations into markers for lineage tracing.
Method: A tumor was first sampled by a large punch biopsy and scanned for any significant degree of heteroplasmy in
a set of sequences containing known mutational hotspots of the mitochondrial genome. A heteroplasmic tumor was
sliced at a 12 μm thickness and placed on membranes. Laser capture micro-dissection was used to take 25000 μm2
subsamples or spots. After DNA amplification, cycling temperature capillary electrophoresis (CTCE) was used on
the laser captured samples to quantify mitochondrial mutant fractions.
Results: Of six testicular tumors studied, one, a Leydig tumor, was discovered to carry a detectable degree of
heteroplasmy for two separate point mutations: a C→ T mutation at bp 64 and a T→ C mutation found at bp
152. From this tumor, 381 spots were sampled with laser capture micro-dissection. The ordered distribution of
spots exhibited a wide range of fractions of the mutant sequences from 0 to 100% mutant copies. The two
mutations co-distributed in the growing tumor indicating they were present on the same genome copies in the
founding cell.
Conclusion: Laser capture microdissection of sliced tumor samples coupled with CTCE-based point mutation
assays provides an effective and practical means to obtain maps of mitochondrial mutational heteroplasmy
within human tumors.
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Introduction
The mitochondrial genome (mtDNA) is a circular DNA
molecule [1, 2] of around 16.5 kb. Multiple copies of
mtDNA are found in each mitochondrion and a human
cell may have between 100 and 10000 copies [3], de-
pending on cell type. In early studies of somatic mtDNA
mutations in tumors, it was suggested that somatic
mitochondrial mutations can grow from a low frequency
of occurrence (heteroplasmy) to become completely
dominant (homoplasmy). Homoplasmy was reported to
be found in more than half of human tumors [4–8].
Later studies, however, have found this number to be
significantly lower [9, 10]. Hypothetical paths to homo-
plasmy, however, can be offered as mathematical models
based on random drift linked to mtDNA replication dur-
ing cell division and in the absence of selection [5, 11, 12].
The basic hypothesis is that once a mutation arises in an
organogenic stem cell as a single copy of mtDNA, this
mutant copy may be retained in a stem cell lineage and by
random distribution result in some stem cells to contain a
significant fraction of a particular mutant mtDNA copy. If
said stem cell becomes the first tumor stem cell then sub-
sequent tumor stem cell divisions would be expected to
continue random distribution of mutant copies so that
after multiple divisions some descendant copies would
contain no mutant copies (wild type homoplasmy) while
others would have all copies carrying the mutant sequence
(mutant homoplasmy) with most stem cells distributed
with intermediate forms of mutant heteroplasmy.
It is generally believed that most tumors are heteroge-
neous with infiltrations of non-tumor cells [13]. Sam-
pling of only tumor-derived cells is therefore difficult. As
non-tumor cells would not carry the mutation present in
tumor cells it would not be possible to distinguish be-
tween heteroplasmy and homoplasmy in a random
tumor sample [14, 15]. Pathological evaluation is often
used to locate the tumor tissue. The success of this
method depends on the experience of the pathologist
and the quality of staining [8, 16–18].
Somatic mtDNA mutations have been used as a marker
of clonality in human tissues or tumors [11]. A successful
method has been the immuno-histochemical marking of
cytochrome oxidase (COX) deficient cells [19–21].
In Taylor et al. [3], selected individual colonic crypts
were sequenced and sixty mitochondrial mutations
were detected, of which half were homoplasmic. None
of the mutations were identical. The probability of in-
dependent identical homoplasmic mutations can be
assumed to be very low, as is also predicted by the
mathematical model [11].
Laser capture microdissection (LCM) was introduced
in 1996 [22]. The method uses a laser to cut selected
areas of tissue resting on a membrane. The area of inter-
est can be collected by gravity or by adherence and is
transferred to post processing vials. LCM has been used
to capture spots of tissue for the analysis of proteins,
mRNA and DNA [23–26].
This study describes a method to trace somatic mito-
chondrial mutations through a tumor slice. In a first
step, DNA from a large representative piece of tissue is
analyzed to detect the presence of mtDNA mutations. If
mutations are found, LCM is used to obtain several
small spots of the tissue. Cycling capillary temperature
electrophoresis (CTCE) [27–30] is used to detect and
quantify mutant fractions in each sample. In the course
of this study, more than 900 LCM samples were ana-
lyzed for the presence of mtDNA mutations.
Materials and methods
Tissue samples
Surgical discharges were collected under informed consent
at the surgical departments of Bærum sykehus (Vester
Viken, Helse sør-øst, Norway) in 2015. Similarly, liver
samples were collected as surgical discharges under in-
formed consent at the University Hospital in Bologna
(Policlinico Sant’Orsola-Malpighi, Bologna, Italy) as part
of a different study.
According to the regional ethics comity (REC), “tech-
nical and methodological development work that uses
anonymized biological material” does not require approval
from REC (https://helseforskning.etikkom.no/ikbViewer/
page/reglerogrutiner/soknadsplikt/sokerikkerek?p_dim=34
999&_ikbLanguageCode=us).
Six samples of testicular cancer, five germ cell tumors,
and one Leydig cell tumor were snap-frozen in liquid ni-
trogen and stored at −70 °C until DNA extraction was
performed. Fresh frozen samples have been shown to have
better DNA integrity than formalin fixed, paraffin embed-
ded samples [31]. All samples were anonymized with an
arbitrary number.
DNA extraction
A representative sample of each tissue was obtained by
inserting a blunt end 19G 11/2 hypodermic needle
(Microlance3, Becton Dickinson, Ireland) through the fro-
zen tissue. DNA was extracted from the core sample by
Blood & Cell Culture DNA Mini Kit (Qiagen, Valencia,
California USA). DNA was eluted with elution buffer (as
recommended by manufacturer) and stored at −20 °C. The
DNA from these samples was analyzed for somatic mito-
chondrial mutations.
First round PCR
Segments of mtDNA that have previously shown to con-
tain many somatic mutations [32] were amplified with
mitochondrial-specific primers to avoid amplification of
homologeous regions in the nuclear DNA. Five sets of
mitochondrial specific primer pairs were used, resulting
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in amplification product between 714 and 928 base pair
in length (see Table 1).
The PCR reaction mixture contained 0.1 μl of ex-
tracted DNA (~5 ng), 0.8 mM dNTPs (0.2 mM of each
dNTP) (VWR, Oslo, Norway), 1X Thermopol Buffer,
2 mM MgSO4, 0.075unit Taq/μl, 0.15 μM of each for-
ward, reverse and fluorescently labeled primer (Inte-
grated DNA Technologies, Leuven, Belgium) and total
reaction volume of 10 μl. The temperature cycling was
performed in an Eppendorf Mastercycler ep gradient S
(Eppendorf, Hamburg, Germany) with an initial denatur-
ation 94 °C for 240 s followed by cycling 38 times under
the following conditions, denaturation at 94 °C for 15 s,
annealing for 40 s with temperature given in Table 1 and
elongation at 72 °C for 150 s.
Capillary electrophoresis
All first round amplification products were checked and
visualized by capillary electrophoresis in MegaBACE
1000 DNA Analysis System (GE Healthcare Life Sci-
ences, Pittsburgh, PA, USA). Samples were loaded into
the capillaries from 96-well plates by electrokinetic in-
jection at 161 V/cm for 20 s. The temperature of the ca-
pillary chamber was set to 27 °C and electrophoresis was
carried out at a constant field of 145 V/cm.
Second round PCR
Template for second round PCR was 0.8 μl of a 1:200 di-
lution (first round PCR in H2O). The templates were
dispensed into 96-wells plates with a syringe dispenser
(Hydra 96, Robbins Scientific, USA). To each well 10 μl
reaction mixture was added, consisting of 1xThermopol
Reaction Buffer with 2 mM MgS04, 0.3 μM forward pri-
mer, 0.15 μM 1/2GC-tailed “reverse” primer, 0.15 μM, 6-
Carboxyfluorescein-GC-clamp primer, 500 μM dNTP,
100 μg Bovine Serum Albumine (Sigma-Aldrich, Oslo,
Norway) and 0.75U Cloned Pfu DNA polymeraze. Plates
were sealed with two strips of electrical tape (Clas
Ohlson, Oslo, Norway). The temperature cycling was re-
peated 25 times; 94 °C for 15 s, annealing temperature
(given in Table 2) held for 30 s and extension at 72 °C
for 60 s.
Tumor analysis
Testicular tumor samples were obtained from six pa-
tients. Apparent normal tissues adjacent to the tumor
were marked with a suture (by the surgeon responsible
for removing the tumor) and snap frozen in liquid nitro-
gen. The suture was used as a reference when the sam-
ple was mounted in the cryotome. DNA extracted from
the testicular tumor samples were analyzed for somatic
mutations in the hotspot regions of the mtDNA. The
fragments selected were based on the results of scanning
76% of the mtDNA in 94 tumor samples from 13 differ-
ent tissues origin [32].
Tissue sectioning
Sample with somatic mitochondrial mutations was
mounted to a cryostat sample holder with a water-
soluble glycols and resins matrix (Tissue-Tek® O.C.T.
Compound, Sakura, Finetek, USA). The sample holder
temperature was set to −20 °C and the knife temperature
to −23 °C. The cryostat (Leica CM1950) cut 12 μm sec-
tions. Each cut was gently transferred to either a steel
framed polyethylene naphthalate membrane (Leica, Leica
Microsystems, Wetzlar, Germany) or glass microscope
slide (Thermo Scientific, Gerhard Menzel, Braunschweig,
Germany).
Cycling temperature capillary electrophoresis
CTCE analysis was performed for the selected fragments
as previously described [28]. In brief; a 96-capillary DNA
analyzer (MegaBACE 1000) was used to analyze 6-
carboxyfluorescein labeled PCR products. Mutant PCR
amplicons were separated from the wild type by cycling
the temperature around the capillaries. The cycling
temperature was based on the theoretical melting
temperature, for each fragment, calculated by Poland’s
algorithm [29, 33] in the implementation described by
Steger [34, 35]. The separation temperature proposed by
the algorithms was adjusted based on the urea concentra-
tion in the matrix. The instrument was modified to allow
for elevated temperature cycling [27, 36]. Temperature
cycling was programmed in the macro.ini file used by the
Instrument Control Manager (ICM) software package
(GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Table 1 Primers used to selectively amplify mtDNA
Annealing
# Start (b p) End (b p) Length (b p) “Forward” primer (5′–3′) “Reverse” primer (5′–3′) Temperature (°C)
23 15924 201 846 aAACCGGAGACGAAAACCTTTTTC aCTTTAGTAGGTATGTTCGCCTGT 51
1 16521 880 928 aCCATAAAGCCTAAATAGCCCACA aCCAACCCTGGGGTTAGTATAGCT 54
10 6917 7671 754 aTGCTCTGAGCCCTAGGATTCATC aTGAGGGCGTGATCATGAAAGGTG 55.5
16 10852 11566 714 aGCCTAATTATTAGCATCATCCCC aATGCCTCATAGGGATAGTACAAG 51
22 15169 15993 824 aGAGGGGCCACAGTAATTACAAAC aTGGGTGCTAATGGTGGAGTTAAA 51
a = tail sequence (CGCCCGCCGCGCCCCGCG)
Refinetti et al. BMC Clinical Pathology  (2017) 17:6 Page 3 of 9
The injection and running electric fields were as
given for the first round amplicons.
Internal standard
The two heteroplasmic mutations found in the initial
sample analysis were re-amplified with a 5′ ROX-labeled
primer. These were used as internal standards during
electrophoresis and were injected into all capillaries in
all runs prior to sample injection. The internal standard
serves as a control of the separating temperature and as
a marker for the DNA mutations.
Tissue sectioning
Fixing and staining
The membrane and the glass slide with the 12 μm tissue
section were dried at room temperature and fixed in
pure methanol (Sigma-Aldrich) for 10 min, followed by
subsequently air drying of the methanol residue. The tis-
sue was stained with Giemsa azur eosin methylene blue
solution (Merck, Damstadt, Germany) (diluted 1/20 with
H2O) for 30 min. Slides are then submerged into 1%
acetic acid in H2O solution for 30 s (differentiation) and
immediately rinsed in water. The stained tissue was air
dried prior to imaging by microscope.
Laser capture microdissection
A Leica LDM 6000 was used to take images of tissue
sections mounted on membrane or glass slides. The soft-
ware, Leica laser microdissection V6.7.1.3952, was used
to control the microscope when taking pictures or
selecting areas for laser capture microdissection and cut-
ting. A hardware modification was made to the collec-
tion unit allowing for samples to be collected into two
strips of 8 PCR caps (VWR, Oslo, Norway).
20 μl of a collection solution (1×Thermopol buffer
with Proteinase K, 0.27 μg/μl) was added to each cap in
the inverted strips. After cutting and collecting the se-
lected areas by laser capture microdissection, the strips
(with collection liquid and tissue) were mounted onto a
96-well PCR plate (Axygen, VWR, Oslo, Norway). The
plate was briefly centrifuged and incubated at 56 °C for
30 min. Deactivation of proteinase K was achieved by
raising the temperature to 95 °C for 1 min. One micro-
liter of incubated solution was used as template for the
first round PCR (see above).
Results
Of the six testicular tumors analyzed, the sample from
the Leydig cell tumor was found to have two mutations,
one in fragment 2 and one in fragment 4 (Table 2). The
Table 2 Primers used to amplify fragments suitable for detecting mutation by CTCE
Template,fragment# Annealing
# Start(bp) End(bp) fromfirstPCR “Forward” primer(5′–3′) “Reverse” primer(5′–3′) Temperature (°C)
1 16569 25 1 aTGCATGGAGAGCTCCCGTGAGTGG CCCCTTAAATAAGACATCACGAT 52
2 42 126 1 aATTAACCACTCACGGGAGCTCTC AGGATGAGGCAGGAATCAAAGAC 55
4 131 181 1 aCACCCTATGTCGCAGTATCTGTC CACACTTTAGTAAGTATGTTCGC 55
6 483 153 1 aGGGGTTAGCAGCGGTGTGTGTGTG TCCCACTCCCATACTACTAATCT 55
7 530 633 1 aTACCCAGCACACACACACCGCTG CAAACCTATTTGTTTATGGGGTGA 55
8 673 705 1 aTTAGAGGGTGAACTCACTGGAAC GGTTTGGTCCTAGCCTTTCTATT 58
82 7031 1734 10 aACGACACGTACTACGTTGTAGCC AATATGATAGTGAAATGGATTTT 52
84 7340 7416 10 aCTTTCTTCCCACAACACTTTCTC TCTCAAATCATGAAAATTATTAAT 55
125 11029 11086 16 aTTAGGAGGGGGGTTGTTAGGGGGT CATCCCTCTACTATTTTTTAACC 58
127 11193 11243 16 aACCAGCCAGAACGCCTGAACGCA GGTGTTGTGAGTGTAAATTAGTG 55
128 11283 11311 16 aTGTGCCTGCGTTCAGGCGTTCTGG TAATCATATTTTATATCTTCTTC 60
130 11437 11492 16 aTTGACCCAGCGATGGGGGCTTCGA GAGCCAACAACTTAATATGACTA 55
176 15201 15257 22 aAGAATCGTGTGAGGGTGGGACTGT AGTAATTACAAACTTACTATCCG 60
177 15274 15377 22 aAGTAGACAGTCCCACCCTCACAC GGTGATTTTATCGGAATGGGAGG 60
178 15394 15448 22 aCTAGGAATCACCTCCCATTCCGA TAATGTCATTAAGGAGAGAAGGAA 55
181 15761 15864 22 aACCTCCTCATTCTAACCTGAATC CAGGCCCATTTGAGTATTTTGTTT 55
184 16080 16130 23 aCAAGTATTGACTCACCCATCAAC ACAGGTGGTCAAGTATTTATGGTA 57
185 16170 16272 23 aGTGGGTGAGGGGTGGCTTTGGAGT CCAATCCACATCAAAACCCCCTC 56
187 16263 16366 23 aAACTGCAACTCCAAAGCCACCCC CCCTATCTGAGGGGGGTCATCCAT 58
a=tailsequence(CCCGCCGCCCCCGCCCGGG)
GC-Clamp=(6FAM-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGGG)
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two mutations were identified as base pair substitutions,
C to T at base pair 64 and a T to C at base pair 152
(NC_012920.1). None of the other five tumors had any
mutations in the fragments analyzed. Figure 1 shows the
electropherograms for the fragments with a mutation.
Finding only one sample with a mitochondrial mutation
was less than expected, but is not significant when con-
sidering the small number of samples.
In the first step the DNA was extracted by needle bi-
opsy taken through the tumor sample. It, therefore, con-
tains a mixture of DNA from cells across the tumor.
The presence of a detectable mutation fraction found in
this way suggests that sampling by LCM might identify
the same mutation. In the other tumors, no mutations
were found, which suggests that none is present or the
fraction is too low.
The sample with two mutations was taken to the next
step in the procedure. Figure 2 shows an image of a sec-
tion of the tissue with two mutations. The red circle in-
dicates the area determined as normal by the surgeon.
Ninety-three circular spots (~25000 μm2) were dissected
by LCM and dropped into separate caps. For each sam-
ple, fragments 2 and 4, in which a mutation was found,
were analyzed.
To estimate the number of cells in a LCM sample,
Giemsa stained dark blue nuclei were counted in 48 cir-
cles, by two researchers. The average number of nuclei
observed was 31 with a standard deviation of 13 and a
range of 7 to 76 nuclei/circle. The theoretical upper
bound can be calculated assuming an average cell diam-
eter of 20 μm. This gives a total of ~80 cells.
The mitochondrial DNA copy number in the LCM
samples was determined by real-time PCR. LCM sam-
ples homoplasmic for both mutations (black circles) and
wild type (white circles) were analyzed, and no differ-
ence in mtDNA copy number could be detected. The
copy number was 300 per cell.
Figure 3 displays the LCM spots for which the mutant
fraction could be determined for both mutations (color-
coded by white and black circles). The combined LCM
and PCR success rate was 86 and 76% for the two
markers, respectively. In some samples, other mutants
that do not co-elute with the internal standard have
been marked with a different color. The inserted electro-
pherograms demonstrate the allele separation and quan-
tification of mutant fraction found in three different
spots for each marker. The mutant fraction was calcu-
lated based on the peak heights and have previously
been shown to have a linear relationship between signal
and mutant fraction [29]. From these data, close to
homoplasmic mutated regions could be identified for
each marker.
Following this first analysis, a further 186 LCM sam-
ples were taken from the remaining part of the tissue
section, as shown in Fig. 4. The mutant fraction could
be determined in a large fraction of samples (89% and
91%) as shown in Fig. 4. The location of the spots for
the second part of the analysis were selected by a sub-
jective assessment of visible structures in Fig. 4. Subse-
quent review of the data in Figs. 3 and 4 did, however,
not reveal any clear relation between apparent tissue
structure and observed mutant fraction.
a b
c d
Fig. 1 Electropherogram of mutated fragments detected by cycling temperature capillary electrophoresis. Electropherograms a) and c) show
non-mutated samples, while electropherograms b) and d) show the two mutations found in one sample
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To validate the procedure, a new section approxi-
mately 50 μm below the first one was analyzed. To elim-
inate possible biases, the samples were collected as two
fixed grids (8x6) in Fig. 5. The success rate in determin-
ing the mutant fraction was 98 and 100%. The positions
at which homoplasmic mutations can be observed in
Fig. 5, correlate with those in Fig. 3. Six areas with near
homoplasmic mutations in Fig. 3, are matched to six
nearby areas in Fig. 5.
In addition, spots mostly show similar mutant frac-
tions for both markers. The correlation was 0.75. It is
reasonable to conclude that these mutations occur to-
gether, i.e., an mtDNA either contains both mutations
or none.
The method was subsequently used to analyze two in-
dependent liver samples (a cholangio- and a hepato- cel-
lular carcinoma). Both tumors had known mitochondrial
mutations (study in progress). Each sample was
Fig. 2 Overview of sample harboring two mutations. The red circle indicates suture position attached by the surgeon to indicate normal tissue.
Image was taken with the LCM microscope by scanning the sample
Fig. 3 Laser capture microdissected spots with mutants fractions. Marker detected by primer set # 2 is on the top and marker detected by primer
set #4 is on the bottom. White is associated with the first peak (homoduplex) in electropherogram, and black is associated with the second peak
(homoduplex). The fraction of white and black in each circle, represent the fraction of the first and second variant respectively in each sample.
Other color presents mutants not aligning with the internal standard in the electropherogram. Inserted electropherograms represent homoplasmic
regions and heteroplasmic areas (e.g., mix of two cell population)
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subjected to LCM and mutation analysis in the grid–like
sampling scheme as shown for the testis sample. Figure 6
displays the results of the 288 spots cut from each tissue.
The upper section (cholangio carcinoma) is dominated
by one mtDNA type and has heteroplasmic spots with a
low mutant fraction in some areas. Only one spot,
indicated by the arrow, is almost homoplasmic for the
mutation, but in fact, the electropherogram showed the
presence of a third mutation at a low fraction. The lower
section of Fig. 6 (hepatocellular carcinoma) has multiple
spots of near homoplasmic mutations as well as several
heteroplasmic spots.
Fig. 4 Laser capture microdissected spots with mutants fractions. Marker detected by primer set # 2 is on the top and marker detected by primer
set #4 is on the bottom. White is associated with the first peak (homoduplex) in electropherogram, and black is associated with the second peak
(homoduplex). The fraction of white and black in each circle, represent the fraction of the first and second variant respectively in each sample.
Other color presents mutants not aligning with the internal standard in the electropherogram. Inserted electropherograms represent
homoplasmic regions and heteroplasmic areas (e.g., mix of two cell population)
Fig. 5 Focused laser capture microdissection in a grid of 8×6 spots. Marker detected by primer set # 2 is on the top and marker detected by
primer set #4 is on the bottom. Enlargement show adjacent different homoplasmic areas. Scale bar is 178 μm long
Refinetti et al. BMC Clinical Pathology  (2017) 17:6 Page 7 of 9
Discussion
This paper describes a method to sample and analyze
mutations from spots of a tumor tissue. The novelty lies
in the small size of the samples or spots (25000 μm2 or
an average of 31 cell) and the systematic distribution of
the samples. Since each cell carries multiple mitochon-
dria and each mitochondrion has multiple copies of
mtDNA, dissecting such a small number of cells gives
enough templates for PCR amplification. This would not
be sufficient for detecting mutations in nuclear DNA. In
our studies we observed that it is better to distribute the
spots on a regular grid, rather than placing them accord-
ing to visible structures. The results give a demonstra-
tion of the efficacy of tracing the distribution of mutant
mitochondrial genomes across a slice from a tissue or a
tumor. This method could be used for studies of
humans or experimental animals.
Because the LCM instrument depended on gravitation,
spots smaller than 25000 μm2 resulted in a higher laser
capture failure rate (data not shown). Increasing the size
of the spots risks dilution of the mutant fraction, leading
to a potential sampling bias.
Because the probability of independent occurrence of
an identical mutation in the mtDNA of a cell is very
small, the observed results are consistent with a clonal
expansion of cells. To place an upper bound on this
probability, a fragment not having any mutation but sit-
uated in a hotspot region of the mtDNA (d-loop) was
analyzed in 700 LCM samples. No mutations were
found. The probability of independently acquiring a
given mutation can thus safely be placed below 1/700.
Some estimates put it much lower at around 10−30 [19].
To further strengthen the argument, macroscopic sam-
ples of 94 tumors were analyzed [32]. One hundred and
forty-two high fraction mtDNA mutations were se-
quenced and none of them were identical.
In the specific case of the testicular tumor analyzed
here, two homoplasmic mutations 88 base pairs apart
are detected and traced. Since the presence of these mu-
tations is highly correlated, it suggests that one cell
lineage is being observed, and not a series of independ-
ent events.
The method described is sensitive and provides a
quantitative way to explore any tissue for heteroplasmy.
Under our optimized conditions, the cost of analyzing
300 spots is about $30 (not including the cost of a
trained technician working for three days). Once hetero-
plasmy with a sufficiently large mutant fraction has been
established, it can, for example, be used to explore the
resection margins of a tumor. Furthermore, if a continu-
ous stack of sections cut by microtome were available,
investigating mitochondrial mutations in three dimen-
sions becomes possible. This would advance the field of
three-dimensional lineage tracing in humans.
Conclusion
The method presented in this study can be used for
lineage tracing in humans. Its capacity was demonstrated
in human tumors and can be extended to the study of me-
tastasis and normal tissue. Using a regular sampling grid
of LCM spots is shown to be essential to study tumor
heterogeneity.
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